It was Goldman Sachs' day (8 AM PDT) -- and Dr. Permutter did take at least one oblique swipe at the price of Gilead's SovaldiTM today, by repeatedly emphasizing that a Hep C cure, at an "efficient, effective cost" would be an extremely big win for any pharma able to make it happen. By that, I am certain, he means at something like one half the at-the-moment price tag ($84,000 for 12 weeks) of Gilead's world beating Hep C cure. All oral is the way to go -- and shorter durations (thus the promise of Idenix, on this past "Merger" Monday).
Here's the bit -- via Reuters:
. . . .Merck research chief Roger Perlmutter said the No. 2 U.S. drugmaker would consider big acquisitions of biotech companies for their medicines, rather than to obtain their drug-development technologies.
Perlmutter was speaking on Thursday to analysts and investors at the annual Goldman Sachs healthcare conference being held in Rancho Palos Verdes, at the Terranea Resort. . . .
Seems like that might suggest Merck won't just be buying patent estates -- Dr. Perlmutter wants actual products. Makes sense.